Insulin glargine (Insulin U300)

Drug Profile

Insulin glargine (Insulin U300)

Alternative Names: HOE901-U300; Insulin glargine U300; Insulin U300; LantusXR; Toujeo

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 11 Nov 2016 Interim pharmacodynamics and pharmacokinetics data from a phase II trial in Type 1 diabetes mellitus released by Sanofi
  • 01 Nov 2016 Sanofi completes a phase III trial for Type-2 diabetes mellitus in United Kingdom, Germany and Austria (NCT02585674; EudraCT2014-004533-13)
  • 01 Nov 2016 Launched for Type-2 diabetes mellitus in Turkey (SC) (NCT02954692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top